Work

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Cancer

DOI: 10.1002/cncr.28701

Authors: David S. Hong, Ignacio Garrido‐Laguna, Suhendan Ekmekcioglu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina Piha‐Paul, Apostolia M. Tsimberidou, YueJin Wen, Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, National Institutes of Health, National Cancer Institute, University of California San Diego, Moores Cancer Center

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Cancer Institute, National Center for Research Resources, NIH Clinical Center

Awards: G1901027039, Center for Clinical and Translational Sciences, Phase I Studies of Targeted Anti-Cancer Therapies, Cancer Center Support Grant

OpenAlex ID: W1588528216

FWCI: 2.049

Cites: 44

Cited by: 27

Related to: 10